-
1.发明授权Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient 有权包含抗GRP78抗体作为活性成分的药物组合物公开(公告)号：US08192740B2
公开(公告)日：2012-06-05
申请号：US12449778
申请日：2008-02-27
申请人： Naoki Kimura
发明人： Naoki Kimura
CPC分类号： C07K16/28 , A61K47/6811 , A61K47/6817 , A61K47/6843 , A61K2039/505 , C07K16/30 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/77
摘要： An object of the present invention is to provide novel pharmaceutical compositions using anti-GRP78 antibodies. More particularly, the present invention provides a novel method of cancer treatment using anti-GRP78 antibodies, novel cell growth inhibitors and anticancer agents that contain anti-GRP78 antibodies, as well as novel anti-GRP78 antibodies. The present inventor prepared antitumor antibodies to target GRP78, the localization of which in cancer cells changed to the cell membrane. The inventor successfully obtained an anti-GRP78 antibody that would bind specifically to the cell surface of cancer cells, leading to the accomplishment of the above-mentioned objects.
摘要翻译： 本发明的目的是提供使用抗GRP78抗体的新型药物组合物。 更具体地，本发明提供了使用抗GRP78抗体的癌症治疗的新方法，含有抗GRP78抗体的新型细胞生长抑制剂和抗癌剂，以及新的抗GRP78抗体。 本发明人制备靶向GRP78的抗肿瘤抗体，其在癌细胞中的定位改变为细胞膜。 本发明人成功地获得了特异性结合癌细胞表面的抗GRP78抗体，从而完成了上述目的。
-
公开(公告)号：US20150276749A1
公开(公告)日：2015-10-01
申请号：US14434259
申请日：2012-10-09
发明人： Takeshi Isoda , Nao Noro , Tomonori Kaneko
IPC分类号： G01N33/574
CPC分类号： G01N33/57492 , C07K14/705 , C07K16/28 , G01N33/57423 , G01N2333/705
摘要： The present invention provides a method by which lung squamous cell carcinoma can be detected in a simple and prompt manner with high detection performance; and the like. The method according to the present invention detects lung squamous cell carcinoma by an assessment including the steps of: (1) performing measurement of the desmoglein 3 content in a blood sample collected from a subject; and (2) comparing the desmoglein 3 content determined by the measurement with the desmoglein 3 content in a blood sample collected from a healthy individual so as to estimate the presence of lung squamous cell carcinoma in the subject when the desmoglein 3 content is higher in the blood sample collected from the subject.
摘要翻译： 本发明提供了一种能够以高检测性能简便快速地检测肺鳞状细胞癌的方法。 等等。 根据本发明的方法通过评估包括以下步骤来检测肺鳞状细胞癌：（1）进行从受试者收集的血液样品中的骨髓蛋白3含量的测量; 和（2）将由测定确定的脱骨髓素3含量与从健康个体收集的血液样品中的骨髓来蛋白3含量进行比较，以估计当骨髓蛋白3含量较高时，受试者中肺鳞状细胞癌的存在 从受试者收集的血液样本。
-
3.发明申请Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient 有权包含抗HB-EGF抗体作为活性成分的药物组合物公开(公告)号：US20100266502A1
公开(公告)日：2010-10-21
申请号：US12584360
申请日：2009-09-03
申请人： Naoki KIMURA
发明人： Naoki KIMURA
CPC分类号： C07K16/22 , A61K47/48546 , A61K47/6845 , A61K51/1018 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2319/30 , G01N33/57484
摘要： An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers.
摘要翻译： 公开了具有内在活性的抗HB-EGF抗体。 细胞毒性物质优选与本发明的抗HB-EGF抗体结合。 还提供了包含本发明的抗体作为活性成分的抗癌剂和细胞增殖抑制剂，治疗癌症的方法和诊断癌症的方法，其包括施用本发明的抗体 。 可以用本发明的抗癌剂治疗的癌症包括胰腺癌，肝癌，食管癌，黑素瘤，结肠直肠癌，胃癌，卵巢癌，子宫颈癌，乳腺癌，膀胱癌，脑肿瘤和 血液癌。
-
4.发明申请公开(公告)号：US20100209439A1
公开(公告)日：2010-08-19
申请号：US12666418
申请日：2008-06-25
申请人： Kenji Yoshida
发明人： Kenji Yoshida
IPC分类号： C07K16/30 , A61K39/395
CPC分类号： C07K16/2896 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/72
摘要： An objective of the present invention is to provide antibodies that bind to Prominin-1 and have ADCC activity and/or CDC activity, and pharmaceutical compositions containing those antibodies as an active ingredient.To achieve a solution to the above-mentioned objective, the present inventors produced recombinant antibodies by cloning a nucleotide sequence of the AC133 antibody variable region, discovered that the ADCC/CDC-inducing effect which does not exist in the original AC133 antibody is imparted to the recombinant antibodies, and thereby completed the present invention. In the human chimeric antibody/human effector cell combination, the chimeric antibody whose constant region sequence had been converted to human IgG1/κ was found to induce strong ADCC. Furthermore, the present inventors produced humanized antibodies prepared by grafting the AC133 antibody CDRs to a human antibody sequence, and further produced humanized antibodies having binding activities equivalent to the activity of the chimeric antibody by introducing amino acid substitutions into the humanized L chain sequence. The present invention provides unlabeled AC133 human chimeric antibodies and humanized antibodies having antitumor effects.
摘要翻译： 本发明的目的是提供结合Prominin-1并具有ADCC活性和/或CDC活性的抗体，以及含有这些抗体作为活性成分的药物组合物。 为了实现上述目的的解决方案，本发明人通过克隆AC133抗体可变区的核苷酸序列产生重组抗体，发现赋予原始AC133抗体中不存在的ADCC / CDC诱导作用赋予 重组抗体，从而完成了本发明。 在人嵌合抗体/人效应细胞组合中，其恒定区序列已转化为人IgG1 / 被发现诱导强ADCC。 此外，本发明人通过将AC133抗体CDR移植到人抗体序列而制备人源化抗体，并通过将人源化L链序列引入氨基酸取代而进一步制备具有与嵌合抗体活性相当的结合活性的人源化抗体。 本发明提供了未标记的AC133人嵌合抗体和具有抗肿瘤作用的人源化抗体。
-
5.发明申请Chimeric Fc-gamma Receptor and Method for Determination of ADCC Activity by Using the Receptor 有权嵌合Fc-γ受体和使用受体测定ADCC活性的方法公开(公告)号：US20100035280A1
公开(公告)日：2010-02-11
申请号：US12525031
申请日：2008-01-30
申请人： Shigeto Kawai
发明人： Shigeto Kawai
IPC分类号： G01N33/567 , C07K14/705 , C07H21/04 , C12N15/63 , C12N5/10
CPC分类号： G01N33/566 , C07K14/70535 , C07K16/18 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/732 , C07K2319/00 , G01N33/5014 , G01N2500/04 , G01N2500/10
摘要： An objective of the present invention is to provide chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human Fcγ receptor transmembrane domain, or chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human γ chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors.To accomplish the above-mentioned objectives, the present inventors produced chimeric molecules by fusing the extracellular domain of mouse FcγR3 or mouse FcγR4 with the transmembrane domain/intracellular domain of human γ chain or human FcγR3, and expressed the chimeric molecules in human NK92 cells. It was revealed that the ADCC activity can be induced by the chimeric receptors produced by any combination of the domains, and that the ADCC activity of mouse antibodies can be measured using the chimeric receptors of the present invention.
摘要翻译： 本发明的目的是提供含有小鼠Fcγ受体细胞外结构域和人Fcγ受体跨膜结构域的嵌合受体或含有小鼠Fcγ受体细胞外结构域和人γ链跨膜结构域的嵌合受体。 本发明的另一个目的是提供使用嵌合受体测量小鼠抗体的ADCC活性的方法和筛选具有ADCC活性的小鼠抗体的方法。 为了实现上述目的，本发明人通过将小鼠FcgammaR3或小鼠FcγR4的细胞外结构域与人γ链或人FcγR3的跨膜结构域/细胞内结构域融合而产生嵌合分子，并在人NK92细胞中表达嵌合分子。 显示ADCC活性可以由通过结构域的任何组合产生的嵌合受体诱导，并且可以使用本发明的嵌合受体来测量小鼠抗体的ADCC活性。
-
公开(公告)号：US08546546B2
公开(公告)日：2013-10-01
申请号：US12667595
申请日：2008-07-03
申请人： Kiyotaka Nakano
发明人： Kiyotaka Nakano
CPC分类号： G01N33/57438 , A61K2039/505 , C07K16/3092 , C07K2317/24 , C07K2317/41 , C07K2317/732 , G01N33/57446 , G01N2333/4725
摘要： An antibody that binds to Mucin17 (Muc17) is disclosed. The antibody of the present invention preferably binds to the peptide of SEQ ID NO:3 and does not bind to the peptide of SEQ ID NO:4 or the peptide of SEQ ID NO:5. Also disclosed are an anti-cancer agent, preferably an anti-cancer agent for pancreatic cancer, which comprises the antibody of the present invention, as well as a method of diagnosing cancer using the antibody of the present invention, preferably the antibody of the present invention that does not bind to the secreted-form of Muc17.
摘要翻译： 公开了结合粘蛋白17（Muc17）的抗体。 本发明的抗体优选与SEQ ID NO：3的肽结合，不与SEQ ID NO：4的肽或SEQ ID NO：5的肽结合。 还公开了包含本发明的抗体的抗癌剂，优选为胰腺癌的抗癌剂，以及使用本发明的抗体诊断癌症的方法，优选本发明的抗体 本发明不结合Muc17的分泌型。
-
公开(公告)号：US20120128678A1
公开(公告)日：2012-05-24
申请号：US13138880
申请日：2010-04-15
IPC分类号： A61K39/395 , G01N33/566 , A61P35/00 , C07K16/18 , C12Q1/68
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/30 , C07K16/40 , C07K2317/24 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/76 , G01N33/57423 , G01N33/57442 , G01N2333/96433
摘要： [Problem to be Solved]An object of the present invention is to provide novel means for the treatment and diagnosis of cancer.[Solution]The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect based on internalization activity and is promising as a therapeutic target. Moreover, this antibody has neutralization activity against protease activity and is also expected to have effect brought about by the inhibition of TMPRSS11E functions.
摘要翻译： [待解决的问题]本发明的目的是提供用于治疗和诊断癌症的新颖手段。 [解决方案]本发明人获得了针对TMPRSS11E的单克隆抗体，发现该抗体结合天然形式的TMPRSS11E，并且流式细胞术中TMPRSS11E在癌细胞系的细胞膜上高度表达。 该抗体基于内化活性表现出抗体依赖性细胞介导的细胞毒活性（ADCC活性）和抗肿瘤作用，并且作为治疗靶标是有希望的。 此外，该抗体具有抗蛋白酶活性的中和活性，并且也预期具有通过抑制TMPRSS11E功能而产生的作用。
-
公开(公告)号：US20120014870A1
公开(公告)日：2012-01-19
申请号：US13140351
申请日：2009-12-25
IPC分类号： A61K51/10 , C40B30/00 , C07K16/30 , G01N33/574
CPC分类号： C07K16/2869 , C07K5/1008 , C07K5/1013 , C07K2317/732 , C07K2317/734 , G01N33/57449
摘要： With dedicated research, the present inventors discovered that not only the LGR7 gene but also the LGR7 protein are highly expressed in clear cell adenocarcinoma cells of ovarian cancer. Furthermore, the present inventors found that anti-LGR7 antibodies have antibody-dependent cell-mediated cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity against LGR7-expressing cells. From the above findings, the present inventors discovered that the anti-LGR7 antibodies are useful for diagnosis, prevention, and treatment of primary and metastatic ovarian clear cell adenocarcinoma.
摘要翻译： 通过专门的研究，本发明人发现，不仅LGR7基因而且LGR7蛋白都在卵巢癌的透明细胞腺癌细胞中高度表达。 此外，本发明人发现抗LGR7抗体具有针对LGR7表达细胞的抗体依赖性细胞介导的细胞毒性（ADCC）活性和补体依赖性细胞毒性（CDC）活性。 从上述发现，本发明人发现抗LGR7抗体可用于诊断，预防和治疗原发性和转移性卵巢透明细胞腺癌。
-
公开(公告)号：US20110262929A1
公开(公告)日：2011-10-27
申请号：US12998988
申请日：2009-12-22
申请人： Shigeto Kawai , Naoki Kimura
发明人： Shigeto Kawai , Naoki Kimura
CPC分类号： C07K16/30 , C07K16/28 , C07K16/40 , C07K2317/73 , C07K2317/732 , G01N33/57423 , G01N33/57438 , G01N33/57449
摘要： The present invention provides antibodies that bind to HS6ST2 proteins, pharmaceutical compositions comprising the antibodies as active ingredients, methods for diagnosing cancer using the antibodies, HS6ST2 proteins conjugated to cytotoxic agents and pharmaceutical compositions comprising the HS6ST2 proteins as active ingredients.
摘要翻译： 本发明提供结合HS6ST2蛋白的抗体，包含抗体作为活性成分的药物组合物，使用抗体诊断癌症的方法，与细胞毒性剂缀合的HS6ST2蛋白和包含HS6ST2蛋白作为活性成分的药物组合物。
-
公开(公告)号：US09079957B2
公开(公告)日：2015-07-14
申请号：US13138880
申请日：2010-04-15
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , C07K16/40 , G01N33/574 , A61K39/00
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/30 , C07K16/40 , C07K2317/24 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/76 , G01N33/57423 , G01N33/57442 , G01N2333/96433
摘要： [Problem to be Solved]An object of the present invention is to provide novel means for the treatment and diagnosis of cancer.[Solution]The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect based on internalization activity and is promising as a therapeutic target. Moreover, this antibody has neutralization activity against protease activity and is also expected to have effect brought about by the inhibition of TMPRSS11E functions.
摘要翻译： [待解决的问题]本发明的目的是提供用于治疗和诊断癌症的新颖手段。 [解决方案]本发明人获得了针对TMPRSS11E的单克隆抗体，发现该抗体结合天然形式的TMPRSS11E，并且流式细胞术中TMPRSS11E在癌细胞系的细胞膜上高度表达。 该抗体基于内化活性表现出抗体依赖性细胞介导的细胞毒活性（ADCC活性）和抗肿瘤作用，并且作为治疗靶标是有希望的。 此外，该抗体具有抗蛋白酶活性的中和活性，并且也预期具有通过抑制TMPRSS11E功能而产生的作用。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.02 秒)
